Skip to search formSkip to main contentSkip to account menu

K 12.148

Known as: K 12148, K-12148, K12.148 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

lifibrol

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
Clinical pharmacology of the hypocholesterolemic agent K 12.148 (lifibrol) in healthy volunteers
SummaryK 12.148 (INN: lifibrol), a new cholesterol synthesis inhibitor, was studied in healthy volunteers to evaluate tolerance… 
2005
2005
Clinical pharmacology of the hypocholesterolemic agent K 12.148 (lifibrol) in healthy volunteers
SummaryK12.148 (INN: lifibrol), a new cholesterol synthesis inhibitor, was studied in healthy volunteers to evaluate tolerance… 
2000
2000
The effects of lifibrol (K12.148) on the cholesterol metabolism of cultured cells: evidence for sterol independent stimulation of the LDL receptor pathway.
1996
1996
Biotransformation of lifibrol (U-83860) to mixed glyceride metabolites by rat and human hepatocytes in primary culture.
Lifibrol (U-83860), K12.148) is a lipid-lowering drug that has the potential to accumulate in the liver and induce hepatic… 
1995
1995
A novel assay for cytosolic 3-hydroxy-3-methylglutaryl-coenzyme A synthase activity using reversed-phase ion-pair chromatography: demonstration that Lifibrol (K12.148) modulates the enzyme activity.
Cytosolic HMG-CoA synthase and microsomal 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase catalyze two sequential steps in the… 
1993
1993
Action of the new hypolipidemic agent lifibrol (K12.148) on lipid homeostasis in normal rats: Plasma lipids, hepatic sterologenesis, and the fate of injected [14C] acetate
Lifibrol, a new hypocholesterolemic agent with activity in humans, was examined in normal rats for its short-term and long-term… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)